tert-butyl 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)piperazine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)piperazine-1-carboxylate
• 英文别名: Tert-butyl 4-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]piperazine-1-carboxylate；tert-butyl 4-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]piperazine-1-carboxylate
• 化学式: C₂₀H₃₇N₃O₄
• 分子量: 383.531
• InChiKey: OCEAURBAOSLWLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  62.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-(piperidin-4-ylmethyl)piperazine
  参考文献：
  名称：

  BIS-DIAZENIUMDIOLATE COMPOUNDS AS ANTI-CANCER AGENTS

  摘要：

  提供了一系列双组分的双O2-芳基重氮二氧酸盐衍生物，每个分子可以释放高达四个一氧化氮分子。这些化合物对癌细胞具有细胞毒性活性，如人类白血病、乳腺癌和肺癌。其中，化合物3对人类白血病细胞表现出最高的特异性活性。

  公开号：

  US20190106396A1
• 作为产物：
  描述：

  N-Boc-4-哌啶甲醇 在 potassium carbonate 、 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 tert-butyl 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)piperazine-1-carboxylate
  参考文献：
  名称：

  BIS-DIAZENIUMDIOLATE COMPOUNDS AS ANTI-CANCER AGENTS

  摘要：

  提供了一系列双组分的双O2-芳基重氮二氧酸盐衍生物，每个分子可以释放高达四个一氧化氮分子。这些化合物对癌细胞具有细胞毒性活性，如人类白血病、乳腺癌和肺癌。其中，化合物3对人类白血病细胞表现出最高的特异性活性。

  公开号：

  US20190106396A1

文献信息

• BIS-DIAZENIUMDIOLATE COMPOUNDS AS ANTI-CANCER AGENTS
  申请人：Arizona board of regents on behalf of Arizona State University

  公开号：US20190106396A1

  公开（公告）日：2019-04-11

  A series of double-component, bis O 2 -aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.

  提供了一系列双组分的双O2-芳基重氮二氧酸盐衍生物，每个分子可以释放高达四个一氧化氮分子。这些化合物对癌细胞具有细胞毒性活性，如人类白血病、乳腺癌和肺癌。其中，化合物3对人类白血病细胞表现出最高的特异性活性。
• Bis-diazeniumdiolate compounds as anti-cancer agents
  申请人：ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

  公开号：US10556875B2

  公开（公告）日：2020-02-11

  A series of double-component, bis O2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.

  本研究提供了一系列双组分、双 O2- 芳基二氮杂环戊烷衍生物，其中每个分子可释放多达四个一氧化氮分子。这些化合物对人类白血病、乳腺癌和肺癌等癌细胞具有细胞毒活性。其中，化合物 3 对人类白血病细胞的特异性活性最高。
• Double-component diazeniumdiolate derivatives as anti-cancer agents
  作者：Xun Ji、Qi Chen、Viswanath Arutla、Omar Khdour、Qiong-Ying Hu、Shengxi Chen

  DOI：10.1016/j.bmc.2020.115405

  日期：2020.4

  In this study, we synthesized a series of double-component O-2-aryl diazeniumdiolate (DDNO) derivatives, of which each molecule can release up to four nitric oxide molecules. These compounds showed cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, compound 1 (DDNO-1) showed the highest specific activity to human leukemia cells. It induced cell apopotosis and arrest cell cycle of G(2)/M phase. The JNK and p38 protein kinases were activated by compound 1 to induce cancer cell apoptosis. Compound 1 also increased pro-apoptotic Bax level, which is a same function compared to a reported NO donor, JS-K. More interestingly, it decreased the level of an anti-apoptotic member Bcl-2, which is an opposite effect compared to JS-K. Compound 1 could be developed as a new anti-cancer agent since it increases the Bax/Bcl-2 ratio to overcome the drug resistance.